ヒトのCD20に対する治療用抗体の結合機構
Anand Kumar1,2,3, Cyril Planchais4,5, Rémi Fronzes3,6
1Membrane Protein Mechanisms Unit, Institut Pasteur, 75015 Paris, France.
Science (New York, N.Y.)
|August 15, 2020
まとめ
治療用モノクローナル抗体 (mAbs) のタイプIとIIは,CD20を標的とする結合メカニズムが異なっている. II型mAbsは末端複合体を形成し,I型mAbsはB細胞悪性腫瘍と自己免疫疾患の治療を改善するために補完体活性化を高める.
科学分野:
- 免疫学
- 構造生物学
- 生物化学
背景:
- CD20を標的にするモノクローナル抗体 (mAbs) は,B細胞悪性腫瘍と自己免疫疾患の主要な免疫療法です.
- I型とII型の治療用mAbsは,異なるCD20相互作用メカニズムにより,B細胞に明確な結合特性と細胞毒性効果を発揮する.
研究 の 目的:
- タイプIとタイプIIの抗CD20mAbsの差分結合と効果器の構造的基礎を明らかにする.
- 異なる抗CD20抗体クラスの異なる治療効果の基礎となる分子機構を理解する.
主な方法:
- クリオ電子顕微鏡 (cryo-EM) を使用して,リトゥキシマブ,オファトゥムマブ,オビヌツズマブとの複合体における全長CD20の高解像度構造 (3. 74. 7 Å) を決定した.
- CD20と異なるmAb型間の相互作用を定量化するために,結合熱力学を分析した.
主要な成果:
- Cryo-EM構造は,独特の複合体を明らかにした.タイプII mAbs (オビヌツズマブ) は,さらなるmAbまたはコンプリメント結合を阻害する末端複合体を形成する.
- I型mAbs (リトゥキシマブ,オファトゥムマブ) は,種子として作用し,局所的なmAb濃度と効率的な補完体活性化を促進する複合体を形成します.
- オファトゥムマブ複合体は,タイプI抗体間の補完の募集に最適な幾何学を示した.
結論:
- この研究は,タイプIとタイプIIの抗CD20 mAb結合と効果因子機能の異なる分子メカニズムを明らかにした.
- これらのメカニズムの理解は,次の世代のCD20標的免疫療法の合理的な設計に不可欠です.
- 構造的な洞察は,強化された治療抗体を改良するための基盤を提供します.
関連する概念動画
01:26Antibody Actions
2.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.1K
01:10Antibody Structure
64.8K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
64.8K
01:31Hybridoma Technology
16.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.8K
01:25Antibody Structure and Classes
7.9K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
7.9K
01:24B Cell Activation and Differentiation
15.5K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.5K